Items where Author or Contributor is "Davies, CT"
 | Up a level |
Number of items: 6.
2018
Davies, C;
Taylor, A;
Gundogdu, O;
Wren, WB;
Elmi, A;
Dorrell, N;
(2018)
Investigating the biogenesis of Campylobacter jejuni outer membrane vesicle production.
[Conference or Workshop Item]
https://researchonline.lshtm.ac.uk/id/eprint/4648049
Full text not available from this repository.
Valiente, E;
Davies, C;
Mills, DC;
Getino, M;
Ritchie, JM;
Wren, BW;
(2018)
Vibrio cholerae accessory colonisation factor AcfC: a chemotactic protein with a role in hyperinfectivity.
Scientific reports, 8 (1).
p. 8390.
ISSN 2045-2322
DOI: https://doi.org/10.1038/s41598-018-26570-7
2017
Davies, C;
Taylor, A;
Gundogdu, O;
Wren, WB;
Elmi, A;
Kelly, D;
Dorrell, N;
(2017)
Investigating the biogenesis of Campylobacter jejuni outer membrane vesicle production.
[Conference or Workshop Item]
https://researchonline.lshtm.ac.uk/id/eprint/4648039
Full text not available from this repository.
Stabler, RA;
Rosado, H;
Doyle, R;
Negus, D;
Carvil, PA;
Kristjánsson, JG;
Green, DA;
Franco-Cendejas, R;
Davies, C;
Mogensen, A;
+2 more...
Scott, J;
Taylor, PW;
(2017)
Impact of the Mk VI SkinSuit on skin microbiota of terrestrial volunteers and an International Space Station-bound astronaut.
NPJ Microgravity, 3.
p. 23.
ISSN 2373-8065
DOI: https://doi.org/10.1038/s41526-017-0029-5
2016
Gundogdu, O;
Davies, C;
Liaw, J;
Elmi, A;
Hachani, A;
Wren, WB;
Dorrell, N;
(2016)
Investigation of the role of the Campylobacter jejuni Type VI secretion system in secretion of virulence factors and interactions with host cells.
[Conference or Workshop Item]
https://researchonline.lshtm.ac.uk/id/eprint/4648054
Full text not available from this repository.
2014
Navarro Coy, NC;
Brown, S;
Bosworth, A;
Davies, CT;
Emery, P;
Everett, CC;
Fernandez, C;
Gray, JC;
Hartley, S;
Hulme, C;
+8 more...
Keenan, AM;
McCabe, C;
Redmond, A;
Reynolds, C;
Scott, D;
Sharples, LD;
Pavitt, S;
Buch, MH;
(2014)
The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.
BMC musculoskeletal disorders, 15.
p. 452.
ISSN 1471-2474
DOI: https://doi.org/10.1186/1471-2474-15-452